ZEB2与E-cadherin在前列腺癌发生、发展中的表达意义

Abstract
Figure/Table
References (24)
Related Citation (15)

Download: PDF (640 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the expression significance of zinc-finger E-box binding protein 2 (ZEB2) and E-cadherin in the occurrence and development of prostate cancer. Methods A total of 88 prostate specimens from Tangshan Union Medical College Hospital from January 2016 to March 2019 were selected. Among them, a total of 60 prostate cancer tissues were in the observation group and a total of 28 benign prostate hyperplasia tissues were in the control group. The immunohistochemical SP method was used to detect ZEB2 and E-cadherin protein in the two groups. The relationship between ZEB2 and E-cadherin protein expression and clinicopathological parameters of prostate cancer were analyzed. Results The positive expression rate of ZEB2 and E-cadherin between the two groups were compared, and the differences were highly statistically significant (P ＜ 0.01). The expression of ZEB2 and E-cadherin protein were closely related to the TNM staging and bone metastasis of prostate cancer patients (P ＜ 0.05 or P ＜ 0.01), but had nothing to do with age and Gleason grade (P ＞ 0.05). Spearman rank correlation analysis showed that ZEB2 and E-cadherin protein expression in prostate cancer tissue were negatively correlated (r = -0.377, P ＜ 0.01). Conclusion The high expression of ZEB2 protein and the reduced expression of E-cadherin protein may play an important role in the occurrence and development of prostate cancer.

Key words： Prostate cancer Zinc-finger E-box binding protein 2 E-cadherin Benign prostate hyperplasia

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Yingbin1 LI Dandan2 FU Yuhuan3 YU Xuenong1

Cite this article:

WANG Yingbin1 LI Dandan2 FU Yuhuan3 YU Xuenong1. Significance of ZEB2 and E-cadherin in the occurrence and development of prostate cancer[J]. 中国医药导报, 2020, 17(29): 102-105.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I29/102

[1] Tosoian JJ，Mamawala M，Epstein JI，et al. Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer [J]. J Clin Oncol，2015，33（30）：3379-3385.
[2] Fizazi K，Tran NP，Fein L，et al. Abiraterone plus Prednisone in Metastatic，Castration-Sensitive Prostate Cancer [J]. N Engl J Med，2017，377（4）：352-360.
[3] Dragomir A，Rocha J，Vanhuyse M，et al. Treatment patterns and trends in patients dying of prostate cancer in Quebec：a population-based study [J]. Curr Oncol，2017，24（4）：240-248.
[4] Graff RE，Judson G，Ahearn TU，et al. Circulating antioxidant levels and risk of prostate cancer by TMPRSS2：ERG [J]. Prostate，2017，77（6）：647.
[5] Chen H，Lu WB，Huang C，et al. Prognostic significance of ZEB1 and ZEB2 in digestive cancers：a cohort-based analysis and secondary analysis [J]. Oncotarget，2017，8（19）：31435-31448.
[6] Ding WJ，Zhou M，Chen MM，et al. HOXB8 promotes tumor metastasis and the epithelial-mesenchymal transition via ZEB2 targets in gastric cancer [J]. J Cancer Res Clin Oncol，2017，143（3）：385-397.
[7] Wang Q，Zhang JG，Wang W. Expression and significance of S100P，CD147，and OCT4 in different prostate cancer tissue TNM stages [J]. Genet Mol Res，2015，14（2）：6844-6851.
[8] Mai ZP，Yan WG，Li HZ，et al. Clinical characteristics and outcome of gleason score 10 prostate cancer on core biopsy treated by external radiotherapy and hormone therapy [J]. Chin Med Sci J，2015，30（2）：90-94.
[9] 王行环，刘同族.提高认识规范诊疗——《前列腺癌诊断标准》解读[J].中国卫生标准管理，2011，2（4）：25-27.
[10] Shamir ER，Pappalardo E，Jorgens DM，et al. Twist1-induced dissemination preserves epithelial identity and requires E-cadherin [J]. J Cell Biol，2014，204（5）：839-856.
[11] G?觟ppel J，M?觟ckelmann N，Münscher A. Expression of Epithelial-Mesenchymal Transition Regulating Transcription Factors in Head and Neck Squamous Cell Carcinomas [J]. Anticancer Res，2017，37（10）：5435-5440.
[12] Werden SJ，Sphyris N，Sarkar TR，et al. Phosphorylation of serine 367 of FOXC2 by p38 regulates ZEB1 and breast cancer metastasis，without impacting primary tumor growth [J]. Oncogene，2016，35（46）：5977-5988.
[13] 阮水良，韩晨阳，官俏兵，等.IL-9通过TGF-β/Smad通路诱导胃癌MKN-45细胞上皮-间充质转化[J].中国病理生理杂志，2018，34（10）：1748-1753.
[14] 郑丽，赵敏，昂琳，等.乳腺癌中BCL-6和ZEB2的表达及其意义[J].临床与实验病理学杂志，2017，33（1）：50-54.
[15] 罗庆丰，修穆群，高文，等.ZEB2蛋白表达和E-cadherin蛋白在鼻咽癌转移中的临床意义[J].实用癌症杂志，2019，34（5）：704-706.
[16] 张宁，左丽，肖谜，等.E盒结合锌指蛋白2基因对卵巢癌细胞侵袭及迁移影响的实验研究[J].癌症进展，2019， 17（7）：780-783.
[17] Xavir PLP，Cordeiro YG，Rochetti AL，et al. ZEB1 and ZEB2 transcription factors are potential therapeutic targets of canine mammary cancer cells [J]. Vet Comp Oncol，2018，16（4）：596-605.
[18] Ding C，Luo J，Li L，et al. Gab2 facilitates epithelial-to-mesenchymal transition via the MEK/ERK/MMP signaling in colorectal cancer [J]. J Exp Clin Cancer Res，2016，35：5.
[19] 葛晓晴，杨鲲鹏，任景丽，等.E-钙黏附蛋白和E盒结合锌指蛋白2在非小细胞肺癌中表达及预后[J].中华实用诊断与治疗杂志，2015，29（4）：379-381.
[20] 陈小燕，刘琴，兰康云，等.Srx与E-cadherin在宫颈鳞癌组织中的表达及临床意义[J].免疫学杂志，2015，31（12）：1067-1071.
[21] 李家平，何涛，袁红瑛.GSK-3β和E-cadherin在子宫内膜腺癌中的表达和意义[J].重庆医学，2019，48（2）：288-292.
[22] 陶晓峰，刘畅，付明杰，等.HMGA2和E-cadherin在前列腺癌组织中的表达及意义[J].实用医学杂志，2018， 34（2）：191-194.
[23] 钟晓健，黄洪才，叶东明，等.膀胱尿路上皮癌组织中E盒结合锌指蛋白2、E-钙黏附蛋白的表达变化及其意义[J].山东医药，2016，56（39）：9-11.
[24] 霍小东，张洪典，马钊，等.食管鳞癌预后与E盒结合锌指蛋白2和E-钙黏蛋白表达的关系[J].中华实验外科杂志，2018，35（3）：550-553.